anxiolytic
Terms
undefined, object
copy deck
- Chlordiazepoxide
- long acting BZD
- Clorazepate
- long acting BZD
- Diazepam
- long acting BZD
- Flurazepam
- long acting BZD
- Prazepam
- long acting BZD
- Temazepam
- short acting BZD
- Triazolam
- short acting BZD
- Lorazepam
- short acting BZD
- Oxazepam
- short acting BZD
- Alprazolam
- short acting BZD
- Phenobarbital
- partial and general ton-clonic anti-seizure
- Thiopental
- ultra-short acting barbiturate
- Pentobarbital
- intermediate acting barbiturate
- Secobarbital
- intermediate acting barbiturate
- 4 Non-BZD Non-barbituric for anxiety & sleep disorders
- Buspirone Antihistamines beta-blockers Zolpidem
- Imipramine
- TCA
- Amitriptyline
- TCA
- Desipramine
- TCA
- Nortriptyline
- TCA
- Doxepin
- TCA
- Protriptyline
- TCA
- Clomipramine
- TCA
- Bupropion
- heterocyclic
- Venlafaxine
- heterocyclic
- Trazodone
- heterocyclic
- Fluoxetine
- SSRI
- Sertraline
- SSRI
- Paroxetine
- SSRI
- Fluvoxamine
- SSRI
- Phenelzine
- MAOI
- Isocarboxazide
- MAOI
- Tranylcypromine
- MAOI
- Chlorpromazine
- low potency APD
- Thioridazine
- low potency atypical APD
- Haloperidol
- high potency APD
- Clozapine
- medium potency atypical APD
- Risperidone
- high potency atypical APD
- Olanzapine
- high potency atypical APD
- Lithium
- mood stabilizing drug
- Carbamazepine
- partial and general ton-clonic anti-seizure
- Valproic acid
- absence general tonic-clonic
- Clonazepam
- sedative acute anti-manic effects
- Phenytoin
- partial and general ton-clonic anti-seizure
- Vigabatrin
- partial seizures
- Lamotrigine
- partial seizures
- Felbamate
- poorly controlled partial seizures
- Gabapentin
- partial seizures
- Topiramate
- partial and general ton-clonic anti-seizure
- Tiagabine
- anti-seizure
- Ethosuximide
- absence seizures
- Trimethadione
- absence seizures
- Benzodiazepines
- anti-seizure
- Pregabalin
- partial seizures
- Levadopa
- parkinson’s
- Bromocriptine
- DA-receptor agonist
- Pergolide
- DA-receptor agonist
- Pramipexole
- DA-receptor agonist
- Ropinirole
- DA-receptor agonist
- Selegiline
- MAOI for Parkinson’s
- Trihexyphenidyl
- muscarnic receptor antagonist (parkinson’s)
- Benztropene mesylate
- muscarnic receptor antagonist (parkinson’s)
- Diphenhydramine
- first gen H1 receptor antagonist
- Amantadine
- antiviral parkinson’s drug
- Tolcapone
- COMT inhibitor (parkinson’s)
- Entacapone
- COMT inhibitor (parkinson’s)
- Halothane
- liquid inhalation general anesthetic
- Enflurane
- liquid inhalation general anesthetic
- Isoflurane
- liquid inhalation general anesthetic
- Desflurane
- liquid inhalation general anesthetic
- Sevoflurane
- liquid inhalation general anesthetic
- Nitrous oxide
- gas inhalation general anesthetic
- midazolam
- intravenous BZD general anesthetic
- morphine
- intravenous narcotic general anesthetic
- fentanyl
- intravenous narcotic general anesthetic
- Ketamine
- dissociative intravenous general anesthetic
- Droperidol
- “others†intravenous general anesthetic
- Etomidate
- “others†intravenous general anesthetic
- Innovar
- droperidol [potent antipsychotic agent] + fentanyl (intravenous general anesthetic)
- Propofol
- “others†intravenous general anesthetic
- 6 catagories of intravenous anesthetics
- Barbiturates; BZD; narcotics; propofol; ketamine; others
- 4 stages of anesthesia
- analgesia; excitement; surgical anesthesia; medullary depression
- Two most reliable indications for stage III
- loss of eyelash reflex; regular respiratory pattern
- 5 pharmacokinetic factors affecting induction of inhaled anesthesia
- concentration of gas; pulmonary ventilation; blood solubility; pulmonary blood flow; arteriovenous concentration gradient
- 5 pharmacokinetic factors affecting elimination of inhaled anesthesia
-
blood:gas coefficient;
pulmonary blood flow; pulmonary ventilation; solubility in different tissues; rate of drug elimination and metabolism - 6 groups of preanesthetic medications
- Barbiturates; BZD; penothiazines; narcotics; anti-cholinergics; muscle relaxants
- Cocaine
- ester local anesthetic
- Procaine
- short-acting ester local anesthetic
- Tetracaine
- long-acting ester local anesthetic
- Benzocaine
- ester local anesthetic
- Lidocaine
- intermediate-acting amide local anesthetic
- Mepivacaine
- intermediate-acting amide local anesthetic
- Bupivacaine
- long-acting amide local anesthetic
- Cell types with H1 receptors
- endothelial cells; smooth muscle cells; brain
- H1 receptor activation results
- increase in phosphoinositol hydrolysis and intracellular calcium
- Cell types with H2 receptors
- gastric mucosa; cardiac muscle cells; mast cells
- H2 receptor activity results
- increase cAMP formation
- H3 receptor activity results
- (presynaptic receptor) inhibition of calcium influx = inhibition of transmitter release
- Histamine effects in bronchiolar smooth muscle
- bronchoconstriction mediated by H1
- Histamine effects in secretory tissue
- powerful stimulant of gastric acid secretion mediated by H2 receptors on gastric parietal cells
- Histamine effects in GI tract smooth muscle
- contraction of intestinal smooth muscle mediated by H1
- Histamine effects in nervous system
- powerful stimulant of sensory nerve endings esp those mediating pain and itching
- Chlorpheniramine
- first gen H1 receptor antagonist
- Fexofenadine
- second gen H1 receptor antagonist
- Loratadine
- second gen H1 receptor antagonist
- 6 classes of first gen H1 antagonists
- ethanolamines; ethylenediamines; piperazines; alkylamines; phenothiazines; piperidines
- 2 classes of second gen H1 antagonists
- piperidines
- 4 modulators of stomach gastric acid secretion
- cephalic-vagal axis; gastric distension; mucosal chemical receptors; presence of acid
- Cimetidine
- imidazole quanidine H2 receptor antagonist
- Ranitidine
- guanidine H2 receptor antagonist
- Famotidine
- H2 receptor antagonist
- Nizatidine
- H2 receptor antagonist
- Omeprazole
- irreversible H+/K+ ATPase inhibitor (gastric proton pump)
- Sucralfate
- mucosal protectant (nonabsorbable aluminum salt of sucrose sulfate)
- Colloidal bismuth compounds
- mucosal protectant
- Misoprostol
- cytoprotective agent
- FDA approved method of H. pylori treatment
- clarithromycin (macrolide) and omeprazole (proton pump inhibitor)
- Other H. pylori treatments
- metronidazole; tetracycline; and/or amoxicillin with a H2 receptor blocker or a proton pump inhibitor
- Sulfasalazine
- drug for inflammatory bowel disease (5-aminosalicylic acid [5-ASA] + sulfapyridine linked by azo bond)
- 3 types of immunosuppressive agents used in inflammatory bowel disease
- corticosteroids; cytotoxins; infliximab
- Hydrocortisone
- a corticosteroid used for inflammatory bowel disease
- Azathioprine
- cytotoxin used for inflammatory bowel disease
- Mercaptopurine
- cytotoxin used for inflammatory bowel disease
- Cyclosporine
- cytotoxin used for infammaotry bowel disease
- Infliximab
- monoclonal antibody against TNF-alpha used in inflammatory bowel disease